|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300078461 |
|
最近更新日期: Date of Last Refreshed on: |
2023-12-08 15:24:55 |
|
注册时间: Date of Registration: |
2023-12-08 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
扳机时机对卵巢低反应人群胚胎发育及妊娠结局的影响 |
|
Public title: |
Effects of trigger timing on embryonic development and pregnancy outcome in low ovarian response population |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
扳机时机对卵巢低反应人群胚胎发育及妊娠结局的影响 |
|
Scientific title: |
Effects of trigger timing on embryonic development and pregnancy outcome in low ovarian response population |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
谢奇君 |
研究负责人: |
凌秀凤 |
|
Applicant: |
Qijun Xie |
Study leader: |
Xiufeng Ling |
|
申请注册联系人电话: Applicant telephone: |
+86 183 5199 0290 |
研究负责人电话:
Study leader's |
+86 135 0517 3488 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
qijunXie0806@163.com |
研究负责人电子邮件: Study leader's E-mail: |
lingxiufeng_njfy@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市莫愁路天妃巷123号 |
研究负责人通讯地址: |
江苏省南京市莫愁路天妃巷123号 |
|
Applicant address: |
123 Tianfeixiang, Mochou Road, Nanjing 210004, Jiangsu, China. |
Study leader's address: |
123 Tianfeixiang, Mochou Road, Nanjing 210004, Jiangsu, China. |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南京市妇幼保健院 |
||
|
Applicant's institution: |
Nanjing Maternity and Child Health Care Hospital |
||
|
研究负责人所在单位: |
南京市妇幼保健院 |
||
|
Affiliation of the Leader: |
Nanjing Maternity and Child Health Care Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023KY-018-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京市妇幼保健院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Nanjing Maternity and Child health hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-03-24 00:00:00 | ||
|
伦理委员会联系人: |
陈亚新 |
||
|
Contact Name of the ethic committee: |
Yaxin Chen |
||
|
伦理委员会联系地址: |
江苏省南京市莫愁路天妃巷123号 |
||
|
Contact Address of the ethic committee: |
123 Tianfeixiang, Mochou Road, Nanjing 210004, Jiangsu, China. |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 25 5222 6919 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南京市妇幼保健院 |
||||||||||||||||||||||
|
Primary sponsor: |
Nanjing Maternity and Child Health Care Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市莫愁路天妃巷123号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
123 Tianfeixiang, Mochou Road, Nanjing 210004, Jiangsu, China. |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
研究疾病: |
卵巢低反应 |
||||||||||||||||||||||
|
Target disease: |
Low ovarian response |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
回顾性分析2016年1月至2021年12月在南京市妇幼保健院接受GnRH拮抗剂治疗的波塞冬3型和4型患者,根据触发日优势卵泡大小分为三组。 |
||||||||||||||||||||||
|
Objectives of Study: |
A retrospective analysis was performed on patients with Poseidon type 3 and type 4 who received GnRH antagonist treatment in Nanjing Maternal and Child Health Hospital from January 2016 to December 2021. According to the dominant follicle size on trigger day, they were divided into three groups. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.诊断为不孕症的IVF或ICSI治疗; 2. 行GnRH拮抗剂方案; 3. 卵巢低反应性诊断(根据 Poseidon 标准 3 型、4 型); 4. 取卵周期。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. IVF or ICSI treatment with a diagnosis of infertility; 2. Performing GnRH antagonist regimen; 3. A diagnosis of ovarian hyporesponsiveness (according to Poseidon criteria type 3, type 4); 4. Oocyte retrieval cycle. |
||||||||||||||||||||||
|
排除标准: |
1.严重男性因素不孕(<10^6精子/ml或MESA-TESE获得的精子); 2. PGD/PGS周期; 3.生育能力保存的IVF周期; 4.获卵数为0的周期; 5.卵母细胞冷冻或卵母细胞捐献周期; 6.患有子宫畸形或宫腔形态障碍的女性,如单角子宫、双角子宫、子宫腺疾病、子宫粘膜下肌瘤; 7.有子宫内膜因素的妇女,如子宫内膜息肉、子宫内膜粘连、子宫内膜结核史、输卵管积水导致子宫积液; 8.反复移植失败(既往IVF周期>3)的女性。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Severe male factor infertility (<10^6 sperm /ml or sperm obtained by the MESA-TESE); 2. Genetically indicated IVF cycles (PGD/PGS); 3. IVF cycles for fertility preservation; 4. Canceled cycles that did not reach oocyte retrieval; 5. Oocyte frozen or oocyte donation cycles; 6. Women with uterine malformation or uterine cavity morphology disorders, such as single horn uterus, double horn uterus, uterine glands Disease, uterine submucosal myoma; 7. Women with endometrium factors such as endometrial polyps, intrauterine adhesions, history of endometrial tuberculosis, Hydrosalpinx leads to uterine fluid; 8. Women with repeated transplant failure ( previous IVF cycles >3). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-01-01 00:00:00至 To 2024-06-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-07-01 00:00:00 至 To 2024-02-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2024年6月研究结束后共享原始数据在ResMan平台(https://www.myresman.com/) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
In June 2024 after the end of the study share the original data in ResMan platform (https://www.myresman.com/) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
研究者根据受试者的原始观察记录,将数据及时,完整,正确,清晰地载入病例报告表,录入采用相应的数据库系统双人双机录入,之后对数据库进行两遍对比。电子数据文件分类保存,并有多个备份保存于不同磁盘或记录介质上,妥善保存,防止损坏。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
According to the original observation records of the subjects, the researchers loaded the data into the case report form timely, complete, correct and clear, and entered it into the corresponding database system by two double machines, and then the database was compared twice. Stored in the electronic data file classification, and there are multiple backup save on different disk or on a recording medium, properly kept, prevent damage. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |